{
    "clinical_study": {
        "@rank": "23418", 
        "arm_group": {
            "arm_group_label": "RA-18C3", 
            "arm_group_type": "Experimental", 
            "description": "RA-18C3"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if treatment with RA-18C3 will improve wound\n      healing for patients with pyoderma gangrenosum."
        }, 
        "brief_title": "RA-18C3 Therapy for Subjects With Pyoderma Gangrenosum", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Pyoderma Gangrenosum", 
        "condition_browse": {
            "mesh_term": [
                "Pyoderma", 
                "Pyoderma Gangrenosum"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age:  \u226518\n\n          2. History of pyoderma gangrenosum with or without other systemic disease.\n\n        Exclusion Criteria:\n\n          1. Treatment with any biologicals (including intravenous immunoglobulin) or\n             investigational agents within the last 4 weeks (or 5 half-lives, whichever is\n             longer).\n\n          2. Treatment with corticosteroids or cyclosporine within the last 2 weeks."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01965613", 
            "org_study_id": "2013-PT025"
        }, 
        "intervention": {
            "arm_group_label": "RA-18C3", 
            "description": "IV and Subcutaneous administration", 
            "intervention_name": "RA-18C3", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Pyoderma Gangrenosum", 
        "lastchanged_date": "May 12, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tallahassee", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "32308"
                }, 
                "name": "XBiotech Investigative Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Open Label Study of RA-18C3 in Subjects With Pyoderma Gangrenosum", 
        "overall_contact": {
            "last_name": "Michael D Stecher, M.D", 
            "phone": "512-386-2900"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in Physician's Global Assessment", 
            "safety_issue": "No", 
            "time_frame": "28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01965613"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "XBiotech, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "XBiotech, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}